Lv21
110 积分 2023-05-06 加入
PEMD方案治疗初治早期非上呼吸道消化道或晚期ENKTL患者的有效性及安全性分析
1个月前
已完结
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
1个月前
已完结
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2个月前
已完结
Current treatment approach and future perspectives in B cell lymphoma
2个月前
已完结
DLBCL: who is high risk and how should treatment be optimized?
2个月前
已完结
The current landscape of frontline large B-cell lymphoma trials
2个月前
已完结
Lifestyle interventions in nonalcoholic fatty liver disease
2个月前
已完结
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
2个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
3个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
3个月前
已完结
皖公网安备34019202002308
